Abstract
Agonists targeting subtypes of the nicotinic acetylcholine receptor (nAChR) have been developed and tested for the treatment of cognitive deficits. However, despite over two decades of targeted research, cognitive benefits of these compounds to date have been of uncertain clinical significance, and none has achieved FDA approval for treating cognitive deficits. As possible reasons for this trend, the present chapter considers the choice of nAChR subtypes targeted, the choice of dose, neuroadaptations and withdrawal-induced deficits, and the general premise of pharmacotherapy for cognitive deficits. Possible future strategies are also discussed.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call